BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17549360)

  • 1. Plasma levels and expression of vascular endothelial growth factor-A in human localized prostate cancer.
    Peyromaure M; Badoual C; Camparo P; Grabar S; Goulvestre C; Fulla Y; Vieillefond A; Mao K; Dinh-Xuan AT
    Oncol Rep; 2007 Jul; 18(1):145-9. PubMed ID: 17549360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of vascular endothelial growth factor (VEGF)-A and its receptor in clinically localized prostate cancer: a prospective evaluation in 100 patients undergoing radical prostatectomy.
    Mao K; Badoual C; Camparo P; Delongchamps NB; Vieillefond A; Dinh-Xuan AT; Peyromaure M
    Can J Urol; 2008 Oct; 15(5):4257-62. PubMed ID: 18814815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer.
    George DJ; Regan MM; Oh WK; Tay MH; Manola J; Decalo N; Duggan S; Dewolf WC; Kantoff PW; Bubley GJ
    Urology; 2004 Feb; 63(2):327-32. PubMed ID: 14972483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy.
    Peyromaure M; Camparo P; Badoual C; Descazeaud A; Dinh-Xuan AT
    BJU Int; 2007 May; 99(5):1150-3. PubMed ID: 17437444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy.
    Shariat SF; Anwuri VA; Lamb DJ; Shah NV; Wheeler TM; Slawin KM
    J Clin Oncol; 2004 May; 22(9):1655-63. PubMed ID: 15117988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association of vascular endothelial growth factor receptor-1 with the risk of cancer progression following radical prostatectomy.
    Mao K; Camparo P; Badoual C; Peyromaure M; Delongchamps NB; Vieillefond A; Dinh-Xuan AT
    Oncol Rep; 2008 Jan; 19(1):171-5. PubMed ID: 18097592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
    Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
    Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
    Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of the semaphorin 3A pathway in prostatic cancer.
    Yacoub M; Coulon A; Celhay O; Irani J; Cussenot O; Fromont G
    Histopathology; 2009 Oct; 55(4):392-8. PubMed ID: 19817889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate.
    Li R; Younes M; Wheeler TM; Scardino P; Ohori M; Frolov A; Ayala G
    Prostate; 2004 Feb; 58(2):193-9. PubMed ID: 14716745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia.
    Soulitzis N; Karyotis I; Delakas D; Spandidos DA
    Int J Oncol; 2006 Aug; 29(2):305-14. PubMed ID: 16820871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer.
    Fukuda H; Tsuchiya N; Narita S; Kumazawa T; Horikawa Y; Inoue T; Saito M; Yuasa T; Matsuura S; Satoh S; Ogawa O; Habuchi T
    Oncol Rep; 2007 Nov; 18(5):1155-63. PubMed ID: 17914566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480.
    George DJ; Halabi S; Shepard TF; Vogelzang NJ; Hayes DF; Small EJ; Kantoff PW;
    Clin Cancer Res; 2001 Jul; 7(7):1932-6. PubMed ID: 11448906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma levels of transforming growth factor-1beta and alpha2-macroglobulin before and after radical prostatectomy: association to clinicopathological parameters.
    Sinnreich O; Kratzsch J; Reichenbach A; Gläser C; Huse K; Birkenmeier G
    Prostate; 2004 Nov; 61(3):201-8. PubMed ID: 15368477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue factor and VEGF expression in prostate carcinoma: a tissue microarray study.
    Yao JL; Ryan CK; Francis CW; Kohli M; Taubman MB; Khorana AA
    Cancer Invest; 2009 May; 27(4):430-4. PubMed ID: 19219655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased expressions of vascular endothelial growth factor (VEGF), VEGF-C and VEGF receptor-3 in prostate cancer tissue are associated with tumor progression.
    Yang J; Wu HF; Qian LX; Zhang W; Hua LX; Yu ML; Wang Z; Xu ZQ; Sui YG; Wang XR
    Asian J Androl; 2006 Mar; 8(2):169-75. PubMed ID: 16491267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer.
    Gravdal K; Halvorsen OJ; Haukaas SA; Akslen LA
    Cancer Res; 2009 Jun; 69(11):4708-15. PubMed ID: 19487287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma tissue factor antigen in localized prostate cancer: distribution, clinical significance and correlation with haemostatic activation markers.
    Langer F; Chun FK; Amirkhosravi A; Friedrich M; Leuenroth S; Eifrig B; Bokemeyer C; Francis JL
    Thromb Haemost; 2007 Mar; 97(3):464-70. PubMed ID: 17334515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary levels of vascular endothelial growth factor in patients with prostate cancer as a predictor of disease progression.
    Miyake H; Muramaki M; Kurahashi T; Yamanaka K; Hara I
    Anticancer Res; 2005; 25(5):3645-9. PubMed ID: 16101195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers.
    Shariat SF; Karam JA; Walz J; Roehrborn CG; Montorsi F; Margulis V; Saad F; Slawin KM; Karakiewicz PI
    Clin Cancer Res; 2008 Jun; 14(12):3785-91. PubMed ID: 18559597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.